Patents by Inventor Timothy Yen

Timothy Yen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination of DNA repair inhibition with bendamustine or gemcitabine in the treatment of cancer
    Patent number: 10220051
    Abstract: The invention provides methods for enhancing the cytotoxicity of DNA damage in cancer cells that express thymine DNA glycosylase, and treating tumors accordingly. The methods comprise inhibiting the expression or biologic activity of thymine DNA glycosylase, and inducing DNA damage in the cancer cells. DNA damage may be induced by administration of bendamustine or gemcitabine to the cancer cells.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: March 5, 2019
    Inventors: Alfonso Bellacosa, Timothy Yen, Neil Beeharry, Mitchell Smith, Rossella Tricarico, Vikram Bhattacharjee, Pietro Mancuso
  • Sensitization of cancer cells to DNA damage by inhibiting kinases essential for DNA damage checkpoint control
    Patent number: 9421203
    Abstract: The invention provides methods for overriding cell cycle arrest in a tumor cell, which comprise inducing DNA damage in the cell, and contacting the cell with an amount of bosutinib or a bosutinib isomer effective to inhibit one or more kinase constituents of a DNA damage checkpoint pathway. The invention also provides novel bosutinib isomers, as well as compositions of the novel isomers and the bosutinib isomer 3,5-dichloro-4-methoxyaniline.
    Type: Grant
    Filed: December 9, 2014
    Date of Patent: August 23, 2016
    Assignee: Institute for Cancer Research
    Inventors: Timothy Yen, Neil Beeharry
  • COMBINATION OF DNA REPAIR INHIBITION WITH BENDAMUSTINE OR GEMCITABINE IN THE TREATMENT OF CANCER
    Publication number: 20150164934
    Abstract: The invention provides methods for enhancing the cytotoxicity of DNA damage in cancer cells that express thymine DNA glycosylase, and treating tumors accordingly. The methods comprise inhibiting the expression or biologic activity of thymine DNA glycosylase, and inducing DNA damage in the cancer cells. DNA damage may be induced by administration of bendamustine or gemcitabine to the cancer cells.
    Type: Application
    Filed: November 13, 2014
    Publication date: June 18, 2015
    Inventors: ALFONSO BELLACOSA, TIMOTHY YEN, NEIL BEEHARRY, MITCHELL SMITH, ROSSELLA TRICARICO, VIKRAM BHATTACHARJEE, PIETRO MANCUSO
  • SENSITIZATION OF CANCER CELLS TO DNA DAMAGE BY INHIBITING KINASES ESSENTIAL FOR DNA DAMAGE CHECKPOINT CONTROL
    Publication number: 20150133466
    Abstract: The invention provides methods for overriding cell cycle arrest in a tumor cell, which comprise inducing DNA damage in the cell, and contacting the cell with an amount of bosutinib or a bosutinib isomer effective to inhibit one or more kinase constituents of a DNA damage checkpoint pathway. The invention also provides novel bosutinib isomers, as well as compositions of the novel isomers and the bosutinib isomer 3,5-dichloro-4-methoxyaniline.
    Type: Application
    Filed: December 9, 2014
    Publication date: May 14, 2015
    Inventors: Timothy Yen, Neil Beeharry
  • Combination of DNA repair inhibition with bendamustine or gemcitabine in the treatment of cancer
    Patent number: 8927516
    Abstract: The invention provides methods for enhancing the cytotoxicity of DNA damage in cancer cells that express thymine DNA glycosylase, and treating tumors accordingly. The methods comprise inhibiting the expression or biologic activity of thymine DNA glycosylase, and inducing DNA damage in the cancer cells. DNA damage may be induced by administration of bendamustine or gemcitabine to the cancer cells.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: January 6, 2015
    Assignee: Institute for Cancer Research
    Inventors: Alfonso Bellacosa, Timothy Yen, Neil Beeharry, Mitchell Smith
  • Genes encoding proteins involved in mitotic checkpoint control and methods of use thereof
    Patent number: 6593098
    Abstract: Novel human BUB genes and their encoded proteins are provided herein. The kinases encoded by the disclosed BUB1A and BUB1B genes play a pivotal role in mitotic checkpoint control. BUB3 is a substrate of these kinases, BUB genes and their encoded proteins provide valuable therapeutic targets for the design of anti-proliferative agents which inhibit the aberrant cellular proliferation observed in tumor cells.
    Type: Grant
    Filed: June 1, 2000
    Date of Patent: July 15, 2003
    Assignee: Fox Chase Cancer Center
    Inventors: Timothy Yen, Gordon Chan, Sandra Jablonski